[PDF][PDF] Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Repositioning of drugs to use as antiviral treatment is a critical need [1]. It is commonly very
26 badly perceived by virologists, as we experienced this in reporting the effectiveness of 27 …
26 badly perceived by virologists, as we experienced this in reporting the effectiveness of 27 …
[PDF][PDF] Doxycycline and minocycline drugs as a treatment proposal for inhibition of ARDS and inflammatory cytokine mediators caused by COVID19
MA Mostafa - AIJR Preprints, 2020 - core.ac.uk
ABSTRACT The novel coronavirus 2 (COVID 19) is a highly transmittable viral disease
aroused in Wuhan, China at the end of 2019 and spreads around the world. The …
aroused in Wuhan, China at the end of 2019 and spreads around the world. The …
[HTML][HTML] Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia
N Mori, M Katayama, S Nukaga - Journal of Microbiology, Immunology and …, 2021 - Elsevier
No specific therapy is available for COVID-19. We report the effectiveness and adverse
effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients …
effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients …
[HTML][HTML] Hydroxychloroquine in COVID-19: potential mechanism of action against SARS-CoV-2
Abstract Purpose of Review The rapid spread of virus, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has turned out to be a global emergency. Symptoms of this …
coronavirus 2 (SARS-CoV-2), has turned out to be a global emergency. Symptoms of this …
[HTML][HTML] Immunomodulatory Effects of Pentoxifylline: Profiling Data Based on RAW 264.7 Cellular Signaling
MH Seo, MY Eo, TTH Nguyen, HJ Yang, SM Kim - Applied Sciences, 2021 - mdpi.com
Pentoxifylline (PTX) is a methylxanthine derivative that has been developed as an
immunomodulatory agent and an improvement of microcirculation. Osteoradionecrosis …
immunomodulatory agent and an improvement of microcirculation. Osteoradionecrosis …
Reasons for discontinuing the use of Hydroxychloroquine in the treatment of the Novel Coronavirus
AA Dawood - Asian Journal of Pharmaceutical Analysis, 2021 - indianjournals.com
In March 2020 the world officially released its first approach to the coronaviral pandemic to
explain the rationale for using hydroxychloroquine. It was also believed to calm down the …
explain the rationale for using hydroxychloroquine. It was also believed to calm down the …
Effect of fluvoxamine on cytokine level of COVID-19 patients hospitalized in ICU.
Background: In reviewing the laboratory studies on humans and animals, we observe that
use of certain drugs with specified applications inhibit the immune reactions in the body …
use of certain drugs with specified applications inhibit the immune reactions in the body …
Antiviral treatment of COVID-19
Currently, there is not any specific effective antiviral treatment for COVID-19. Although most
of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe …
of the COVID-19 patients have mild or moderate courses, up to 5%-10% can have severe …
[HTML][HTML] In vitro assessment of the antiviral activity of ketotifen, indomethacin and naproxen, alone and in combination, against SARS-CoV-2
The 2019 coronavirus infectious disease (COVID-19) is caused by infection with the new
severe acute respiratory syndrome coronavirus (SARS-CoV-2). Currently, the treatment …
severe acute respiratory syndrome coronavirus (SARS-CoV-2). Currently, the treatment …
[PDF][PDF] Old drug with new milestone: chloroquine and hydroxychloroquine in SARS-COV-2 (COVID-19) with multifaceted effects in other diseases
Hydroxychloroquine is one of the oldest and widely used anti-malarial drug which can be
beard easily with cost and well leeway, also these drugs have been greet to have efficacy in …
beard easily with cost and well leeway, also these drugs have been greet to have efficacy in …